Massachusetts General Hospital Cancer Center 32 Fruit St FL 7-9, Boston, MA 02114 6177244000 (phone), 6177261949 (fax)
Education:
Medical School Harvard Medical School Graduated: 1999
Procedures:
Vaccine Administration
Conditions:
Anxiety Phobic Disorders Chronic Renal Disease Diabetes Mellitus (DM) Disorders of Lipoid Metabolism Malignant Neoplasm of Female Breast
Languages:
English Spanish
Description:
Dr. Shaw graduated from the Harvard Medical School in 1999. She works in Boston, MA and specializes in Medical Oncology and Internal Medicine. Dr. Shaw is affiliated with Massachusetts General Hospital.
Name / Title
Company / Classification
Phones & Addresses
Alice Tien Chu Shaw Manager
1825 SOUTH ADAMS ST. LLC
2895 Royal Oaks Dr, Tallahassee, FL 32309
Alice Carol Shaw
SHAW & SON'S PRECISION CONTRACTING COMPANY, INC
Alice Shaw President, Director
Alice & Phyllis Inc Eating Place
1435 E Lafayette St, Tallahassee, FL 32301 2895 Royal Oaks Dr, Tallahassee, FL 32309 1415 Timberlane Rd, Tallahassee, FL 32312 220 W Tennessee St, Tallahassee, FL 32301 8508781779
That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. "This is really a pivotal study ... a new standard of care," said Shaw, who has no ties to the drugmakers.
Date: Apr 16, 2018
Category: Health
Source: Google
Roche's Alecensa trounces Pfizer's Xalkori in head-to-head ALK matchup—again
Nobody imagined it would be possible to delay advanced lung cancer progression by this much. Most targeted therapies for lung cancer are associated with a median progression-free survival of roughly 12 months, lead study investigator Alice Shaw said in a statement.
Date: Jun 05, 2017
Category: Health
Source: Google
Norovirus outbreak suspected in numerous Santa Barbara County schools
Schools in the Orcutt School District, which include Alice Shaw, Joe Nightingale, Patterson Road, Pine Grove and Ralph Dunlap schools, as well as ManzanitaCharter School on Vandenberg Air Force Base, are reporting numerous cases of gastrointestinal symptoms consistent with the norovirus, according
Date: May 26, 2017
Category: Health
Source: Google
Pfizer (PFE) Announces XALKORI Approved by FDA for Treatment of Patients with ROS1-Positive Metastatic NSCLC
proval of crizotinib for metastatic ROS1-positive non-small cell lung cancer represents another significant step forward in biomarker-driven cancer care, said Dr. Alice Shaw, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, and principal study investigator. As
Date: Mar 11, 2016
Category: Health
Source: Google
3 Pharmaceutical Giants on the Road to Curing Cancer
cases of non-small cell lung cancer, have an abnormality to the ROS1 gene, according to the pharma giant Pfizer. The drug was also effective for approximately 18 months in patients, longer than the average eight to 12 months seen for some other targeted patients, said Alice Shaw, a lead study author.
Date: Sep 29, 2014
Source: Google
Positive Results Reported for Pfizer Drug against Rare Lung Cancer
According to Dr. Alice Shaw from Massachusetts General Hospital Cancer Center in Boston, and also the lead investigator, this is the first detailed study to determine the effectiveness of crizotinib in a large group of patients. The study also confirms that ROS1 is a bona fide therapeutic target in
Date: Sep 29, 2014
Category: Health
Source: Google
Pfizer drug Xalkori effective against rare lung cancer in clinical trial
"This is the first definitive study to establish crizotinib's activity in a large group of patients with ROS1-positive lung cancer and confirms that ROS1 is a bona fide therapeutic target in those patients," said Dr. Alice Shaw from the Massachusetts General Hospital Cancer Center in Boston.
Date: Sep 29, 2014
Category: Health
Source: Google
Pfizer reports positive results for ROS1 positive lung cancer patients with Xalkori
Dr. Alice Shaw from the Massachusetts General Hospital Cancer Center added, "This is the first definitive study to establish crizotinib's activity in a large group of patients with ROS1-positive lung cancer and confirms that ROS1 is a bona fide therapeutic target in those patients."